fluorobenzenes has been researched along with Thrombosis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diaz, JA; Hawley, AE; Lawrence, DA; Myers, DD; Patterson, KA; Wakefield, TW; Wrobleski, SK; Zhang, X | 1 |
| Kaiser, K; Konstantinides, S; Schäfer, K | 1 |
| Bauersachs, J; Eigenthaler, M; Ertl, G; Firnschild, A; Fraccarollo, D; Frantz, S; Schäfer, A; Tas, P | 1 |
| Barthelemy, G; Bernat, A; Dol, F; Herbert, JM; Rinaldi, M | 1 |
| Bernat, A; Dol, F; Herbert, JM; Rinaldi, M; Sainte-Marie, M | 1 |
5 other study(ies) available for fluorobenzenes and Thrombosis
| Article | Year |
|---|---|
Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects.
Topics: Animals; Apolipoproteins E; Cell Movement; Disease Models, Animal; Fluorobenzenes; Gene Deletion; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Interleukin-6; Male; Mice; Mice, Knockout; Neutrophils; P-Selectin; Pyrimidines; Rosuvastatin Calcium; Serpin E2; Sulfonamides; Thrombosis; Time Factors; Vena Cava, Inferior; Venous Thrombosis | 2013 |
Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
Topics: Animals; Apolipoproteins E; Arteries; Cell Count; Collagen; Disease Models, Animal; Endothelium, Vascular; Female; Fibrin; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Pyrimidines; Regeneration; Rosuvastatin Calcium; Sulfonamides; Thrombosis; Tunica Intima | 2005 |
Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
Topics: Animals; Cell Adhesion Molecules; Chronic Disease; Disease Models, Animal; Endothelium, Vascular; Fluorobenzenes; Heart Failure; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microfilament Proteins; Myocardial Infarction; Nitric Oxide; Phosphoproteins; Phosphorylation; Platelet Activation; Pyrimidines; Rats; Reactive Oxygen Species; Rosuvastatin Calcium; Sulfonamides; Superoxides; Thrombosis; Vasoconstriction; Vasodilation; Ventricular Function, Left | 2005 |
Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist.
Topics: Animals; Bleeding Time; Coronary Circulation; Depression, Chemical; Disease Models, Animal; Dogs; Fibrinolytic Agents; Fluorobenzenes; Humans; Ketanserin; Phenols; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabbits; Serotonin Antagonists; Species Specificity; Thrombosis; Vasoconstriction | 1993 |
Potentiating effect of clopidogrel and SR 46349, a novel 5-HT2 antagonist, on streptokinase-induced thrombolysis in the rabbit.
Topics: Animals; Bleeding Time; Clopidogrel; Drug Synergism; Fibrinolytic Agents; Fluorobenzenes; Jugular Veins; Male; Phenols; Platelet Aggregation Inhibitors; Rabbits; Serotonin Antagonists; Streptokinase; Thrombolytic Therapy; Thrombosis; Ticlopidine | 1993 |